{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:00:11Z","timestamp":1777633211791,"version":"3.51.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This report describes a 57-year-old male patient with metastatic breast cancer who experienced atrial fibrillation during the infusion of utidelone as palliative chemotherapy. All cardiological examinations conducted before treatment were normal. There was no evidence of thyroid dysfunction, nor any objective data indicating acute or chronic cardiovascular disease. Other combination drugs have been used in clinical practice for decades and rarely have proarrhythmic activity. The innovative drug utidelone, independently developed in China, was approved by the National Medical Products Administration (NMPA) of China in 2021 for the treatment of patients with metastatic breast cancer. Cardiotoxicity has not been prominently reported in prior clinical trials of utidelone. Although a definite causal relationship cannot be confirmed, the close temporal association and clinical course suggest that utidelone may have contributed to the arrhythmias. This case highlights the need for careful cardiac monitoring during treatment.<\/jats:p>","DOI":"10.3389\/fonc.2026.1695712","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:30:59Z","timestamp":1777437059000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Atrial fibrillation during palliative chemotherapy with utidelone: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Qihuan","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Cancer Center, Affiliated Hospital of Guangdong Medical University","place":["Zhanjiang, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Affiliated Hospital of Guangdong Medical University","place":["Zhanjiang, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Affiliated Hospital of Guangdong Medical University","place":["Zhanjiang, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Affiliated Hospital of Guangdong Medical University","place":["Zhanjiang, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huadi","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Affiliated Hospital of Guangdong Medical University","place":["Zhanjiang, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zumin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Affiliated Hospital of Guangdong Medical University","place":["Zhanjiang, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"965\u2013","DOI":"10.3390\/cancers14040965","article-title":"Intracranial response rate in patients with breast cancer brain metastases after systemic therapy","volume":"14","author":"Niwinska","year":"2022","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30088-8","article-title":"Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicenter, open-label, superiority, phase 3, randomized controlled trial","volume":"18","author":"Zhang","year":"2017","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.600","article-title":"Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomized controlled trial","volume":"32","author":"Xu","year":"2020","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-016-0297-7","article-title":"Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients","volume":"9","author":"Zhang","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01489-z","article-title":"Male breast cancer: a review on diagnosis, treatment, and survivorship","volume":"26","author":"Bhardwaj","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1255","article-title":"RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"29","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000328757","article-title":"Safety of bevacizumab in patients with metastatic breast cancer","volume":"80","author":"Hamilton","year":"2011","journal-title":"Oncology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-023-00314-w","article-title":"Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials","volume":"10","author":"Wang","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ygyno.2020.07.031","article-title":"Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment","volume":"159","author":"Lee","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0083-1","article-title":"Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference","volume":"36","author":"Th\u00e9ophile","year":"2013","journal-title":"Drug Saf"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euaf027","article-title":"Global, regional, and national burden of atrial fibrillation and atrial flutter from 1990 to 2021: sex differences and global burden projections to 2046\u2013a systematic analysis of the Global Burden of Disease Study 2021","volume":"27","author":"Tan","year":"2025","journal-title":"Europace"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2025.107818","article-title":"Correlation electrical repolarization and membrane hERG abundance in iPSC cardiomyocytes induced by chronic drugs actions on channel trafficking","volume":"135","author":"MacQuaide","year":"2026","journal-title":"J Pharmacol Toxicol Methods"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2021.08.028","article-title":"Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk","volume":"18","author":"Burashnikov","year":"2021","journal-title":"Heart Rhythm"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000003499","article-title":"Inflammatory cytokines and cardiac arrhythmias: from pathogenesis to potential therapies","volume":"87","author":"Obeagu","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40959-025-00363-0","article-title":"Arrhythmias, conduction disorders and sudden cardiac death in cancer patients and survivors: expert opinion of the working groups on cardio-oncology and on electrophysiology of the Hellenic Cardiac Society","volume":"11","author":"Keramida","year":"2025","journal-title":"Cardiooncology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7186","article-title":"Carcinoid syndrome: a review","volume":"12","author":"Gade","year":"2020","journal-title":"Cureus"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3892\/br.2018.1158","article-title":"Atrial fibrillation following treatment with paclitaxel: a case report","volume":"9","author":"Zhao","year":"2018","journal-title":"Biomed Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00280-021-04254-w","article-title":"Cardiovascular toxicity of breast cancer treatment: an update","volume":"88","author":"Papageorgiou","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.71562","article-title":"Risk of heart disease following treatment for breast cancer \u2013 results from a population-based cohort study","volume":"11","author":"Yang","year":"2022","journal-title":"eLife"},{"key":"B22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1695712\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:31:02Z","timestamp":1777437062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1695712\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1695712"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1695712","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1695712"}}